Digestion · 2025
Integrin Inhibitors for Ulcerative Colitis Treatment.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tanaka Takanao, Tominaga Keiichi, Kojimahara Shunsuke, Kanazawa Mimari, Yamamiya Akira, Sugaya Takeshi, Irisawa Atsushi
Аннотация
BACKGROUND: Ulcerative colitis is a diffuse, non-specific inflammatory bowel disease of unknown etiology with recurrent relapse and remission. The mechanisms of immune-mediated inflammation as a pathogenesis of ulcerative colitis have been increasingly elucidated, leading to development of biological agents and low-molecular-weight agents that target specific molecules or disease processes.
SUMMARY: Integrin inhibitors impede ulcerative colitis pathogenesis by selectively inhibiting integrin, an adhesion molecule expressed on leukocytes, thereby suppressing lymphocyte infiltration into gastrointestinal tissues and controlling excessive immune responses at the inflammation site: the intestinal tract.
KEY MESSAGE: This article describes the mechanism of integrin inhibitors' action, the usefulness, and positioning of vedolizumab and carotegrast methyl, which are currently available for clinical use to treat ulcerative colitis, and the status of integrin inhibitor development.
SUMMARY: Integrin inhibitors impede ulcerative colitis pathogenesis by selectively inhibiting integrin, an adhesion molecule expressed on leukocytes, thereby suppressing lymphocyte infiltration into gastrointestinal tissues and controlling excessive immune responses at the inflammation site: the intestinal tract.
KEY MESSAGE: This article describes the mechanism of integrin inhibitors' action, the usefulness, and positioning of vedolizumab and carotegrast methyl, which are currently available for clinical use to treat ulcerative colitis, and the status of integrin inhibitor development.